NCT07369921 Pediatric Pilonidal Sinus Surgical Treatment
| NCT ID | NCT07369921 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zeliha Alicikus |
| Condition | Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-04-30 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-04-30 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of study to evaluate four different treatment options for pilonidal sinus disease in a randomized controlled trial to find the most suitable treatment option.
Eligibility Criteria
Inclusion Criteria: * having sacrococcygeal pilonidal sinus disease * written informed (family) consent were eligible for inclusion in this trial Exclusion Criteria: * Being over 18 years old or under 12 years old * recurrent sacrococcygeal pilonidal sinus disease
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07369921 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 18 Years, studying Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07369921 currently recruiting?
Yes, NCT07369921 is actively recruiting participants. Contact the research team at zelihaakis@gmail.com for enrollment information.
Where is the NCT07369921 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07369921 clinical trial?
NCT07369921 is sponsored by Zeliha Alicikus. The trial plans to enroll 80 participants.